Shanghai Qiangbang Biological Technology

Shanghai Qiangbang Biological Technology, commonly known as Qiangbang Bio, is a clinical-stage biopharmaceutical company headquartered in Shanghai, China. The company focuses on the discovery and development of innovative biologics, particularly bifunctional fusion proteins and antibody-drug conjugates (ADCs) for oncology. Its lead candidate, QB-001, is a PD-L1/TGF-β bifunctional fusion protein designed to overcome immune resistance in the tumor microenvironment. Additionally, the company is advancing QB-002, a Claudin 18.2-targeted ADC, into clinical trials for gastrointestinal cancers. Qiangbang Bio leverages its proprietary technology platforms to create next-generation immunotherapies that address unmet medical needs in cancer treatment. The company is supported by leading venture capital investors and maintains a robust pipeline of early-stage candidates.